James Shannon M.D.

James Shannon M.D.

MannKind Corporation

Dr. Shannon was appointed to the board in August 2017. He most recently served as the chief medical officer of GlaxoSmithKline (GSK), where he was responsible for matters of patient safety, general medical governance, medical ethics and integrity, medical information as well as investigations involving human subjects relating to any GSK medicine in development or on the market.

 

Previously, Dr. Shannon spent more than a decade with Novartis. In his last role with the company, as global head of pharma development, he was responsible for all of Novartis’s development activities, from pre-clinical through Phase 4 and oversaw an annual development budget of approximately $4 billion.

 

Dr. Shannon received his science and medical degrees from Queen’s University in Belfast, Northern Ireland. He serves on the board of directors for MannKind Corporation, a biopharmaceutical company focused on treatments for diabetes; ProQR Therapeutics, a developer of RNA-based therapeutics; Immodulon Therapeutics, a biopharmaceutical company developing novel therapies using mycobacterial agents and MyTomorrows, a health-based platform that collaborates with drug developers to provide early access to treatments for patients who have exhausted all other options.

Back